Skip To Main Content
William Hubbard on Muck Rack

William Hubbard

As seen in: JAMA Network, Mondaq
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with William

Contact William, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease : The TEASE-1 Randomized Clinical Trial

|
By Leonide Saad, Neil M. Bressler, Stephen Tsang, Kimberly Stepien, Paul S. Bernstein, Byron Lam, Ilyas Washington, Michael Gorin, Hendrik P. N. Scholl, Mandeep Singh, Shazia Khan, Mary Frey, Sarah Justus, Sophia Park, Christine Xu, Thomas R. Connor, Dennis P. Han, Judy E. Kim, David Weinberg, William Wirostko, Kurt Pfeifer, Heather L. Toth, Patricia L. Winter, Hannah Sheppard, Amanda Daubert, Potyra Rosa, Elizabeth Nuttall, William Hubbard, Melissa Chandler, Becky Weeks, Anna Matynia, Gabrielle DeBartolomeo, Arsany Makkar, Mahmood Seyd Shah, Robert L. Roseman, Kaushik M. Hazariwala, Krissa Packard, Eleanor Dorsey Veh, Vesper Williams, Kaitlin McKenney, Brittany Rego, Stephanie Moebius, Angela Urmanski, Senad Novic, Kimberley Wegner, Kelliann Farnsworth Ordonez, Donnell Creel, Steven Nusinowitz, Emma Stackpole, Julliane Bacerdo
| JAMA Network Verified
Introduction Stargardt disease (STGD) is an autosomal recessive macular dystrophy with a prevalence of 1 in 6000 to 1 in 10 000, characterized by retinal atrophic lesions, also known as chorioretinal atrophy, involving loss of photoreceptors, retinal pigment epithelium (RPE), and underlying choriocapillaris.1-3 Retinal atrophic lesions cause profound visual disturbances and progressive vision loss, including declines in visual acuity, visual fields, and night vision, as well as chromatopsia,...
Open in Who Shared Issue with article?

Corporate Transparency Act Update

|
By William Hubbard
| Mondaq
Earlier this year, we alerted our clients that new beneficial ownership reporting requirements under the Corporate Transparency Act ("CTA") had taken effect, beginning January 1, 2024. As we enter the fourth quarter, we urge our clients to take the necessary steps to ensure they are in compliance. All subject businesses ("Reporting Companies") must file a Beneficial Ownership Information Report ("BOIR") by the end of the year.
Open in Who Shared Issue with article?
See all 2 articles